A detailed history of Guerra Advisors Inc transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Guerra Advisors Inc holds 50 shares of DNLI stock, worth $872. This represents 0.0% of its overall portfolio holdings.

Number of Shares
50
Holding current value
$872
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 04, 2025

BUY
$12.75 - $15.65 $637 - $782
50 New
50 $726,000

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $2.34B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Guerra Advisors Inc Portfolio

Follow Guerra Advisors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Guerra Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Guerra Advisors Inc with notifications on news.